# A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine

> **NCT03483116** · PHASE2 · COMPLETED · sponsor: **Murdoch Childrens Research Institute** · enrollment: 711 (actual)

## Conditions studied

- Rotavirus Infections

## Interventions

- **BIOLOGICAL:** RV3-BB
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03483116
- **Lead sponsor:** Murdoch Childrens Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-15
- **Primary completion:** 2020-01-27
- **Final completion:** 2020-01-27
- **Target enrollment:** 711 (ACTUAL)
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03483116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03483116, "A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03483116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*